Skip to content

Integra LifeSciences Announces Definitive Agreement To Acquire ACell, Inc. View details

CEO Regarding COVID-19

The global response to the COVID-19 pandemic is an evolving situation, impacting all facets of life. At ACell, Inc., the safety and well-being of our employees and our customers is always our priority. We are actively monitoring ongoing developments, taking steps to ensure that our employees are safe, and will continue provide emergent solutions for surgeons and patients in the area of acute soft tissue reconstruction.

Our products are fully sourced in the US, and we have made modifications to our production processes to avoid interruptions and ensure our quality, manufacturing, and distribution capabilities are not impacted by the current situation. You can read more about the strength of our production capabilities here. All products are available, and ACell’s dedicated team is ready to offer the same level of service our customers have always expected.

We are grateful to every healthcare professional for their steadfast dedication to patient care and their efforts to combat COVID-19. We are sensitive to changing policies and practices at hospitals and healthcare institutions, and committed to abiding by our customers’ requirements. Every member of our team is provided ongoing guidance on how to respond to changing global, national, and local authorities.

In this time of rapid change, ACell remains a steadfast partner for our customers and the patients they treat. Our thoughts are with anyone who has been impacted by the virus, either directly or indirectly, and especially with those healthcare professionals who are on the front lines, caring for those in need.

If you have any questions or concerns, please do not hesitate to reach out to me at

Patrick McBrayer
President & CEO

White Acell Logo
ACell Inc.
6640 Eli Whitney Drive
Columbia, MD 21046
High Contrast Mode